Matching articles for "avanafil"
In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and…
Med Lett Drugs Ther. 2026 May 11; 68(1754):78-9 doi:10.58347/tml.2026.1754e
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.
Eroxon — An OTC Gel for Erectile Dysfunction
The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel ( Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved…
Med Lett Drugs Ther. 2024 Nov 11; 66(1715):181-2 doi:10.58347/tml.2024.1715c
The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel ( Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved OTC and topical treatment for erectile dysfunction. It is also available in the UK and the EU.
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
Med Lett Drugs Ther. 2022 Oct 31; 64(1662):174-5
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction
The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication.…
Med Lett Drugs Ther. 2014 May 12; 56(1442):37-8
The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication. Advertisements on Stendra ’s website imply that it has a faster onset of action than other PDE5 inhibitors.
